WST West Pharmaceutical ServicescompanySEC Filings & Insider Trading Activity 2026
Latest West Pharmaceutical Services (WST) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 17, 2026, a 10-Q quarterly report filed on October 23, 2025, an 8-K current report filed on April 23, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for West Pharmaceutical Services (WST) (SEC CIK 105770), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Manufacturer of integrated containment and delivery systems for injectable drugs, including proprietary packaging and contract manufacturing
- • Emphasis on patient-centric self-injection devices combined with connected health technologies for improved treatment adherence
Risk Factors
- • Regulatory risk: U.S. tariffs and retaliatory tariffs in operational jurisdictions; impact on supply chain currently not material but dynamic and monitored closely
- • Macroeconomic risk: $572.2 million cash held outside the U.S., exposing liquidity to foreign exchange volatility and global economic conditions
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue $805M, up 7.7% YoY ($57.7M increase) for Q3 2025; Proprietary Products $647.5M (+7.7%), Contract-Manufactured Products $157.1M (+8.0%)
- • Operating margin 20.8% vs 21.6% YoY Q3 2025 (down 0.8 pts); adjusted operating margin 21.1% vs 21.5%; gross margin 36.6% vs 35.4% (up 1.2 pts)
Risk Factors
- • Continued COVID-19 impact on supply chain and customer demand remains key operational risk
- • Exposure to foreign currency fluctuations affecting reported results due to international sales
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • CEO Eric M. Green retiring as President, CEO, and Board Chair once successor hired — transition expected H2 2026
- • Board engaging executive search firm; leadership continuity risk elevated during search period
Item 7.01: Regulation FD Disclosure
- • CEO Eric Green announced intent to retire from West Pharmaceutical Services and its Board of Directors
- • Company reaffirmed full-year 2026 financial guidance originally issued in Feb 12, 2026 earnings release
Annual Reports Archive10-K
AI-powered analysis of West Pharmaceutical Services (WST) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of West Pharmaceutical Services (WST) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of West Pharmaceutical Services (WST) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $2.9B | $2.9B | $2.9B | $3.1B |
| Gross Profit | $1.1B | $1.1B | $998.5M | $1.1B |
| Operating Income | — | $676.0M | $569.9M | $584.9M |
| Net Income | — | $593.4M | $492.7M | $493.7M |
| Gross Margin | 39.4% | 38.3% | 34.5% | 35.9% |
| Op. Margin | — | 22.9% | 19.7% | 19.0% |
| Net Margin | — | 20.1% | 17.0% | 16.1% |
| Balance Sheet | ||||
| Total Assets | — | $3.8B | $3.6B | $4.3B |
| Equity | — | $2.9B | $2.7B | $3.2B |
| ROE | — | 20.6% | 18.4% | 15.5% |
Source: XBRL financial data from West Pharmaceutical Services (WST) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 23, 2026 | — | — | — |
8-K | Mar 9, 2026 | — | Analysis | — |
10-K | Feb 17, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
10-Q | Oct 23, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 24, 2025 | Jun 30, 2025 | — | |
10-Q | Apr 24, 2025 | Mar 31, 2025 | — | |
10-K | Feb 18, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 24, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 25, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 25, 2024 | Mar 31, 2024 | — | |
10-K | Feb 20, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 26, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 27, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 27, 2023 | Mar 31, 2023 | — | |
10-K | Feb 21, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 27, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 28, 2022 | Jun 30, 2022 | — | |
10-Q | Apr 28, 2022 | Mar 31, 2022 | — | |
10-K | Feb 22, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 28, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 30, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 30, 2021 | Mar 31, 2021 | — | |
10-K | Feb 23, 2021 | Dec 31, 2020 | — | |
10-Q | Oct 23, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest WST SEC filings in 2026?
West Pharmaceutical Services (WST) has filed a 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 23, 2025, an 8-K current report on April 23, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did WST file its most recent 10-K annual report?
West Pharmaceutical Services (WST) filed its most recent 10-K annual report on February 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view WST 10-Q quarterly reports?
West Pharmaceutical Services (WST)'s most recent 10-Q quarterly report was filed on October 23, 2025. SignalX displays every WST 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has WST filed recently?
West Pharmaceutical Services (WST)'s most recent 8-K was filed on April 23, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find WST insider trading activity (Form 4)?
SignalX aggregates every WST Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does WST file with the SEC?
West Pharmaceutical Services (WST) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new WST filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for West Pharmaceutical Services (WST).
What is WST's SEC CIK number?
West Pharmaceutical Services (WST)'s SEC CIK (Central Index Key) number is 105770. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 105770 to look up all WST filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find WST return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from West Pharmaceutical Services (WST) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of West Pharmaceutical Services SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 51+ filings.